GIST News Briefs

New Nanostructured Lipid Carrier System Could Improve GIST Treatment

Researchers developed a new nanostructured lipid carrier system to deliver imatinib to patients with gastrointestinal stromal tumors (GISTs), as published in Nanomaterials. A small amount of imatinib loaded into the new system will be better than imatinib alone, they said. Imatinib is extensively used for the treatment of GIST. However, the drug can cause side…

Targeting MRP1 Has Therapeutic Potential in Imatinib-Resistant GIST

The N6-methyladenosine (m6A) modification of the multidrug resistance-associated protein 1 (MRP1) mRNA promotes drug resistance in gastrointestinal stromal tumors (GISTs), a new study published in Cancer Letters found. This suggests that MRP1 could be a potential therapeutic target for imatinib-resistant GIST. GISTs are abnormal mesenchymal cell growths of the gastrointestinal tract. Patients undergo complete surgical…

Preoperative Computed Tomography May Underestimate Gastric GIST Size

Researchers suggested that computed tomography (CT) may not be a reliable tool to estimate tumor size for preoperative risk stratification of gastrointestinal stromal tumors (GISTs) in a Chinese population, as published in the European Journal of Surgical Oncology. The study showed an underestimation of the sizes of gastric GISTs by 0.30 cm when compared with…

Novel Multikinase Receptor Inhibitor Shows Therapeutic Potential in GIST

Researchers identified a novel multikinase receptor inhibitor called vorolanib that has potent antiangiogenic and antitumor properties, as published in Molecular Therapy: Oncolytics. The novel kinase receptor inhibitor is also potentially less toxic compared to other similar kinase inhibitors like sunitinib and could be a new therapeutic agent for different cancers including gastrointestinal stromal tumors (GISTs).…

First Patient Treated With THE-630 in GIST Phase 1/2 Trial

The first patient with gastrointestinal stromal tumor (GIST) has been treated with the experimental drug THE-630 as part of an ongoing phase 1/2 clinical trial, according to a press release from Theseus Pharmaceuticals, the developers of the drug. “The initiation of our Phase 1/2 trial in patients with previously-treated advanced GIST is an important milestone…

Clear Panel Design Criteria Can Ensure Accuracy of LCFAOD Diagnosis

Researchers identified guidelines-consistent panels of 37 and 74 genetic conditions following evidence-based analyses of criteria, including long chain fatty acid oxidation disorders (LCFAODs) such as primary carnitine deficiency, carnitine palmitoyltransferase 2 deficiency, and very long-chain acyl-CoA dehydrogenase deficiency, as published in Genetics in Medicine. Other guideline-consistent conditions identified were sickle cell disease, cystic fibrosis (CF),…

GIST Guideline Recommendations

Extragastrointestinal Stromal Tumors May Lead to Worse Outcomes Than GISTs

Extragastrointestinal stromal tumors can have a worse prognosis than gastrointestinal stromal tumors (GISTs), according to a new study published in the Journal of Oncology. However, this is only the case in patients with high risk factors, which include accepted adjuvant therapy, larger tumor size, and tumor necrosis and mitosis. There are currently no clinical guidelines…

T-B Sign May Be a Novel Prognostic Factor for Gastrointestinal Stromal Tumor

The so-called “Torricelli-Bernoulli sign” (T-B sign) could be a characteristic sign of gastrointestinal stromal tumor (GIST), according to the results of a retrospective study published in PLoS One. The T-B sign could also be a potential adverse prognostic factor for GIST. “Thus, targeted therapy with [imatinib mesylate] is needed, and extensive surgery such as extended…

Next post in GIST News Briefs